sonesitatug vedotin
sonesitatug vedotin
PHASE3
Drug Profile
ModalityADC
RouteIV
Therapy AreaOncology
Peak Sales Est$1800M
Formulations[]
Mechanism: ROR1-directed (vedotin payload)
Expert: ROR1-directed antibody-drug conjugate with MMAE payload
Everyday: Delivers chemotherapy directly to cancer cells
Targets: ["ROR1"]
Programs (1)
| Indication | Stage | Key Study | Regional Status |
|---|
| Solid tumors | PHASE1 | — | [] |
Upcoming Catalysts (1)
Sonesitatug - Gastric CLDN18.2+ - Ph3 - Topline
H1 2026
Notes
CLDN18.2 ADC. First wholly-owned AZ ADC in P3.
Data from Supabase · Updated 2026-03-24